Skip to content
sellWeak10b5-1 plan

Randall Moreadith sold $22k of SER

Chief Scientific Officer at Serina Therapeutics, Inc.. 4,304 shares at an average of $5.18, traded Aug 18, 2025, filed Aug 20, 2025.

Warning score
0
Value
$22k
4,304 shares
Holdings after
0
-193% from before
From 52-week low
+27%
low $4.11, close $5.22
From 52-week high
-39%
high $8.63, as of Aug 18, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $22k at market
    0
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -3.3%, 3m -25.7%, 6m -67.7%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

SEROct 9, 2026 · close 2.00
Since filing Aug 20, 2025: -61.5%SPY +23.6% · excess -85.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001708599-25-000097, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Aug 18, 2025MOption exercise
Common Stock10b5-1
+2,227$0.06$1342,227Aug 20, 2025
Aug 18, 2025SOpen-market sale
Common Stock10b5-1
-2,227$5.25$12k0Aug 20, 2025
Aug 20, 2025MOption exercise
Common Stock10b5-1
+2,077$0.06$1252,077Aug 20, 2025
Aug 20, 2025SOpen-market sale
Common Stock10b5-1
-2,077$5.10$11k0Aug 20, 2025
Aug 18, 2025MOption exercise
Stock Option (right to buy)derivative10b5-1
-2,227$0.00$0471,263Aug 20, 2025
Aug 20, 2025MOption exercise
Stock Option (right to buy)derivative10b5-1
-2,077$0.00$0469,186Aug 20, 2025

Related signals

Other insiders at Serina Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
31Weak
SERbuy
Serina Therapeutics, Inc.
Stephen K. Brannan
director
$2,030
1,000 shares
-
46Moderate
SERbuy 3
Serina Therapeutics, Inc.
Jay Venkatesan
director
$1,048
589 shares
-
36Weak
SERbuy
Serina Therapeutics, Inc.
Karen J Wilson
director
$18k
10,100 shares
-
52Moderate
SERbuy 3
Serina Therapeutics, Inc.
Karen J Wilson
director
$37k
20,000 shares
-
46Moderate
SERbuy 3
Serina Therapeutics, Inc.
Richard Peter Marshall
director
$20k
12,183 shares
-
0Weak
SERsell10b5-1
Serina Therapeutics, Inc.
Randall Moreadith
Chief Scientific Officer
$19k
6,500 shares
-100%
10Weak
SERsell10b5-1
Serina Therapeutics, Inc.
Randall Moreadith
Chief Scientific Officer
$98k
39,000 shares
-100%
0Weak
SERsell10b5-1
Serina Therapeutics, Inc.
Randall Moreadith
Chief Scientific Officer
$20k
6,500 shares
-100%
0Weak
SERsell10b5-1
Serina Therapeutics, Inc.
Randall Moreadith
Chief Scientific Officer
$23k
6,500 shares
-100%
0Weak
SERsell10b5-1
Serina Therapeutics, Inc.
Randall Moreadith
Chief Scientific Officer
$7,375
2,500 shares
-100%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Randall Moreadith sold $22k of SER | InsiderTell